Zoledronate Slows Weight Loss and Maintains Fat Mass in Osteopenic Older Women: Secondary Analysis of a Randomized Controlled Trial

[1]  D. Kiel,et al.  Post–Hip Fracture Mortality in Nursing Home Residents by Obesity Status , 2019, Journal of the American Geriatrics Society.

[2]  M. Talbäck,et al.  “Obesity Paradox” Holds True for Patients with Hip Fracture: A Registry-Based Cohort Study , 2019, The Journal of bone and joint surgery. American volume.

[3]  Brett S. Nickerson,et al.  Validity of Field and Laboratory Three-Compartment Models in Healthy Adults , 2019, Medicine and science in sports and exercise.

[4]  L. Mei,et al.  Lrp4 expression by adipocytes and osteoblasts differentially impacts sclerostin's endocrine effects on body composition and glucose metabolism , 2019, The Journal of Biological Chemistry.

[5]  I. Reid,et al.  Fracture Prevention with Zoledronate in Older Women with Osteopenia , 2018, The New England journal of medicine.

[6]  R. Tomlinson,et al.  Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes , 2017, Proceedings of the National Academy of Sciences.

[7]  Lihua Zhou,et al.  Increased trabecular bone and improved biomechanics in an osteocalcin-null rat model created by CRISPR/Cas9 technology , 2016, Disease Models & Mechanisms.

[8]  L. Lix,et al.  Antiresorptive therapy and newly diagnosed diabetes in women: a historical cohort study , 2016, Diabetes, obesity & metabolism.

[9]  L. Rejnmark,et al.  The Effect of Treatment With PTH on Undercarboxylated Osteocalcin and Energy Metabolism in Hypoparathyroidism. , 2015, The Journal of clinical endocrinology and metabolism.

[10]  A. Kaider,et al.  Ibandronate Increases Sclerostin Levels and Bone Strength in Male Patients with Idiopathic Osteoporosis , 2015, Calcified Tissue International.

[11]  K. Toulis,et al.  Bisphosphonates and glucose homeostasis: a population-based, retrospective cohort study. , 2015, The Journal of clinical endocrinology and metabolism.

[12]  J. Cauley,et al.  Postmenopausal weight change and incidence of fracture: post hoc findings from Women’s Health Initiative Observational Study and Clinical Trials , 2015, BMJ : British Medical Journal.

[13]  Noriko Yoshimura,et al.  A Meta‐Analysis of the Association of Fracture Risk and Body Mass Index in Women , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  S. Polyzos,et al.  Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. , 2013, The Journal of clinical endocrinology and metabolism.

[15]  S. Cummings,et al.  Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON‐PFT, and FREEDOM trials , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  D. Cucinotta,et al.  Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis. , 2013, The Journal of clinical endocrinology and metabolism.

[17]  L. Idolazzi,et al.  Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. , 2012, Bone.

[18]  E. Vittinghoff,et al.  Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). , 2011, The Journal of clinical endocrinology and metabolism.

[19]  P. Vestergaard.  Risk of Newly Diagnosed Type 2 Diabetes Is Reduced in Users of Alendronate , 2011, Calcified Tissue International.

[20]  R. DePinho,et al.  Insulin Signaling in Osteoblasts Integrates Bone Remodeling and Energy Metabolism , 2010, Cell.

[21]  I. Reid,et al.  The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. , 2009, The Journal of clinical endocrinology and metabolism.

[22]  G. Karsenty,et al.  Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice , 2008, Proceedings of the National Academy of Sciences.

[23]  M. McKee,et al.  Endocrine Regulation of Energy Metabolism by the Skeleton , 2007, Cell.

[24]  E. Barrett-Connor,et al.  The Relationship Between Weight Loss and All‐Cause Mortality in Older Men and Women With and Without Diabetes Mellitus: The Rancho Bernardo Study , 2002, Journal of the American Geriatrics Society.

[25]  I. Reid,et al.  Determinants of the rate of bone loss in normal postmenopausal women. , 1994, The Journal of clinical endocrinology and metabolism.